🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Breast Cancer Nos Metastatic Recurrent

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients NCT05440227Phase 21 site📍 Taipei PhytoHealth Corporation · Tests: PG2 Lyo. Injection 500mg, Placebo 0.9% normal saline A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan Breast Cancer Proteomics and Molecular Heterogeneity NCT01840293n/a6 sites📍 Cork📍 Dublin📍 Dublin Cancer Trials Ireland Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer NCT04521764Phase 11 site📍 Rochester Mayo Clinic · Tests: Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein, Computed Tomography, Magnetic Reson… ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer NCT07173751Phase 3224 sites📍 Springdale📍 La Jolla📍 Los Alamitos BioNTech SE · Tests: Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC NCT06786026Phase 21 site📍 Shanghai Fudan University · Tests: bevacizumab, QL1706, Nab paclitaxel A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) NCT07208149Phase 1, Phase 21 site📍 Beijing Shenzhen Majory Biotechnology Co., Ltd. · Tests: MR001 Bispecific Antibody for Injection Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer NCT07558733Phase 1, Phase 27 sites📍 Los Angeles📍 Lone Tree📍 Springfield Faeth Therapeutics · Tests: Serabelisib, Sapanisertib, Fulvestrant An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. NCT07357597Phase 441 sites📍 Tucson📍 Hot Springs📍 Little Rock AstraZeneca · Tests: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd) Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC NCT05464082Phase 21 site📍 Salt Lake City University of Utah · Tests: Functional Precision Oncology A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. NCT06371274NA1 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: ATRA, Toripalimab Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer NCT06217874n/a1 site📍 Rochester Mayo Clinic · Tests: Non-Interventional Study Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer NCT06900647Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Bortezomib (B), Cisplatin (CDDP), Bortezomib (B), Bortezomib (B), Cisplatin (CDDP) A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer NCT06957886Phase 32 sites📍 Guangzhou📍 Changsha Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069Phase 139 sites📍 Duarte📍 La Jolla📍 Los Angeles Eli Lilly and Company · Tests: LY4052031, Pembrolizumab Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer NCT06081959Phase 31 site📍 Beijing Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites📍 Gilbert📍 La Jolla📍 Los Angeles A2 Biotherapeutics Inc. · Tests: A2B395, xT CDx with HLA-LOH assay Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642n/a3 sites📍 Phoenix📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Tissue Collection Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec) NCT03758976n/a2 sites📍 Lund📍 Lund Lund University Hospital · Tests: Biopsies, blood A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer NCT07294508Phase 2, Phase 31 site📍 Beijing Shanghai Henlius Biotech · Tests: HLX87 + HLX22, HLX87 + Pertuzumab, T-Dxd + Pertuzumab, THP Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment NCT07467330Phase 31 site📍 Fuzhou Fujian Cancer Hospital · Tests: dalpiciclib + capecitabine + endocrine therapy, dalpiciclib + endocrine therapy Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic NCT07807345Phase 16 sites📍 Orlando📍 Boston📍 Oklahoma City Sutro Biopharma, Inc. · Tests: STRO-006, Pembrolizumab A Study of Tetrathiomolybdate (TM) Plus Capecitabine NCT06134375Phase 1, Phase 23 sites📍 Indianapolis📍 Lebanon📍 New York Dartmouth-Hitchcock Medical Center · Tests: Tetrathiomolybdate, Capecitabine, Pembrolizumab A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer NCT06369285Phase 253 sites📍 Birmingham📍 Phoenix📍 Beverly Hills Puma Biotechnology, Inc. · Tests: Alisertib, Endocrine therapy Chronic Toxicities Related to Treatment in Patients With Localized Cancer NCT01993498NA1 site📍 Villejuif UNICANCER · Tests: blood sampling A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer NCT06471205Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, PD-1 Monoclonal Antibody A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer NCT06202261Phase 1, Phase 22 sites📍 Chongqing📍 Harbin Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: TQB2930 for injection, Paclitaxel for injection (albumin-bound), TQB3616 capsule, Fulvestrant injection, Capecitabine t… A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354Phase 3283 sites📍 Mobile📍 Chandler📍 Duarte Merck Sharp & Dohme LLC · Tests: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy